Profit after tax, before exceptional items, stood at ₹153 crore in the fourth quarter and ₹380 crore for the full year.
Revenue rose 1.8% to ₹1,036.5 crore in the March quarter from ₹1,018 crore a year earlier and 13% sequentially. For the full year FY26, revenue from operations increased 3% year-on-year to ₹3,739 crore.
Also Read: ‘Attractive risk-reward’ — Syngene International shares gain as Macquarie sees 27% upside
EBITDA fell 11.7% to ₹303.4 crore in the quarter from ₹343.6 crore in the corresponding period last year. EBITDA margin stood at 29.3% in the quarter, compared with 33.8% in the year-ago period and 25% for the full year FY26.
Net cash generated during FY26 stood at ₹521 crore.
The company has recommended a final dividend of ₹1.25 per equity share of ₹10 face value for the financial year 2025–26. The company has fixed Friday, June 26, 2026, as the record date for determining eligibility for the dividend. The dividend will be paid within 30 days from the date of shareholders’ approval.
Syngene International Executive Chairperson, Kiran Mazumdar-Shaw, said, “I am pleased to take on the role of Executive Chairperson at Syngene at a pivotal moment in its growth journey. I look forward to working with the new leadership team to shape our next phase of expansion, as we continue to benefit from the rising global demand for outsourcing across the life sciences sector.
Also Read: Syngene International Q3 Results: Net profit dives 89% on large-molecule biologics impact
While biotech funding remains discerning and largely concentrated on late-stage assets, Syngene’s diversified end-to-end business model—from discovery and development to manufacturing gives us both resilience and strategic agility in navigating these market realities.
We are also focused on building new business lines, strengthening our differentiated service offerings, and investing in AI and digital capabilities that will enhance speed, productivity, and value creation for our clients.”
Peter Bains, Managing Director and CEO, Syngene International, said, “Syngene’s full-year revenue from operations grew 3%, and with an EBITDA margin of 25%, performance was in line with our revised full-year guidance.
The overall numbers reflect the specific impact from a single large-molecule biologics client, with the underlying business showing steady momentum. During the year, we continued to invest in new capabilities and emerging modalities such as peptides and ADCs, further strengthening our integrated offering and positioning us for long-term growth.”
Also Read: Syngene CEO Peter Bains quits; Siddharth Mittal to take over from July
Shares of Syngene International Ltd ended at ₹432.30, down by ₹7.70, or 1.75%, on the BSE.
